
Professor of Genomics, Physiology, & Biophysics @WeillCornell Medicine. Co-Founder / COI @BiotiaNYC, @UrsaBio & @Onegevity (@thornehealth)
New York, NY
Joined February 2010
- Tweets9.1K
- Following983
- Followers11.7K
- Likes9.5K
Chris Mason retweeted
$NTLA
"As of today, we have dosed more than 600 patients with our investigational in vivo gene editing therapies. We believe this is more than all other companies in the world combined.
We have up to six years of follow-up on some of these patients, and very importantly, we have yet to see any waning of pharmacodynamic or clinical effect."
—John Leonard President and CEO, during the HAE study update.
Chris Mason retweeted
Anil and @Astro_Kutryk are studying antibiotic resistant bacteria in space with the GEARS study. After sampling different areas of @Space_Station, the bacteria was placed on an antibiotic media and the resistant bacteria were grown for a few days, and then they will be identified by doing PCR in space. We can’t wait to find out what is growing in space!
Chris Mason retweeted
We're going to the Moon. Not just to visit this time, but to stay.
Today I'm launching Moon Life Path: every path to a Moon base, tracked.
NASA, Starship HLS, SpaceX, Blue Origin and China are all racing toward the lunar south pole, with India, Russia and Lockheed close behind.
66 entries so far, each labelled confirmed, planned or speculative. When a date slips, the old one stays visible.
moonlifepath.grok.me
It's a work in progress, so feedback, corrections and ideas are very welcome 🚀
Chris Mason retweeted
Please re-tweet. 🚨 🧬 💻 We're looking for a motivated postdoctoral associate in computational biology to join our lab at Weill Cornell Medicine in New York City and study chromatin remodeling and 3D genome organization. To apply:
barisiclab.weill.cornell.edu…
Latest research from the lab:
nature.com/articles/s41586-0…
Chris Mason retweeted
Cool new result from AlphaGenome 2 paper:
AlphaGenome 1 accepted only 1 Mb of DNA sequence. The new model accepts condition (tissue, cell line, cell type, or cell state) and species as additional context. And they trained on both bulk and single-cell data.
They showed that they can now resolve much more granular regulatory mechanisms. A beautiful functional genomics paper from 2024 did a ton of experimental work to show how a genetic variant associated with several autoimmune diseases was over-activating an immune regulatory gene 290 kb away. The model picked up that signal as clear as day, entirely computationally.
Exciting to see continued improvements in AI for regulatory genomics. Kudos to @adamgayoso, @Avsecz, and the DeepMind team!
Chris Mason retweeted
Cease doomscrolling and start joyreading: the amazing Cecilia Cotta - with her trademark courage and creativity - leads a team at Tessera to a major advance in the field: generating stable CAR-T cells in vivo using LNP mRNA delivery - a key step towards CAR-T scalability and affordability! Gregor- and Rosalindspeed, Tessera! cell.com/cell/fulltext/S0092…
A much-needed positive lead in the ALS therapeutic front. In most ALS cases TDP-43 mediated splicing goes haywire, and things like a junk stretch of DNA or a cryptic exon get spliced in. In human neurons in a dish, genetic correction of a single cryptic splicing event (UNC13A) restored about 80% of synaptic signaling, despite hundreds of other splice errors. So it looks like UNC13A is a very promising target for ALS. Fortunately, current genetic medicine tools make this a very tractable therapeutic strategy.
doi.org/10.1038/s41586-026-1…
Chris Mason retweeted
Specifically in "gene editing meets cardiovascular" space, Verve-Lilly, Editas, CRISPR Tx, Scribe, etc are all developing edits/epiedits that will become effective vaccines, and not in 10 years, but sooner. I'm not a CAD SME, but the editing data look strong.
Chris Mason retweeted
Long read sequencing reveals changes in measured isoform structure and abundance due to RNA processing
“we observed decreased PCR counts associated with higher m6A methylation levels on native RNA”
biorxiv.org/content/10.64898…
Chris Mason retweeted
Our bodies are colonized by trillions of viruses that we live with in homeostasis. The most diverse and abundant of these viral families are anelloviruses. A new paper from us at @MSKCancerCenter explores what happens after we *all* have been infected
biorxiv.org/content/10.64898… 1/n
Excited to share our latest preprint! 🎉
SPACE-Tag enables high-throughput spatial chromatin profiling with CUT&Tag.
Huge congrats to Chao, Ruiyang, Sara, Maros, Silas, Ivan, and Sanja! 👏
🔬 biorxiv.org/content/10.64898…
Chris Mason retweeted
One of the major challenges in the neural #organoid field has been the difficulty of systematically screening large numbers of perturbations. This is important not only for identifying potential therapeutics, but also for uncovering mechanisms that regulate cell-state transitions during human development.
In a new @biorxivpreprint from our lab, we describe a simple, cost-effective, and scalable platform for high-throughput screening in human cortical organoids. The system uses a compact plate washer/dispenser that fits inside a standard biosafety cabinet and can process medium changes for more than 7,000 organoids per hour, substantially reducing the labor required for large-scale organoid culture and screening.
Using this approach, we screened 1,280 compounds targeting major signaling and regulatory pathways across more than 6,000 organoids and identified translational regulation as a modulator of cortical cell-state progression. Transient inhibition of translation elongation shifted cortical progenitors toward neuronal differentiation, with changes in newly synthesized proteins preceding detectable transcriptional changes. We further validated this effect across multiple human stem cell lines, nonhuman primate organoids, and primary human cortical tissue. More on this discovery soon.
This was an enormous effort led by Merve Avar, whose persistence and dedication were remarkable. Grateful for the collaboration with Maria Barna’s lab and to everyone who contributed to this work!
"Targeted ANGPTL3 inactivation in nonhuman primates was well-tolerated and led to a > 90% mean reduction in circulating ANGPTL3 protein, with durability confirmed out to 3 years following a single dose." nature.com/articles/s41586-0…
Chris Mason retweeted
I wrote “Safer: A Playbook” to help people face a personal crisis — a health scare, a job loss, a family conflict — and turn fear into action.
Thank you, @NPR and Marc Silver, for the conversation — and for letting me share the “legendary” PB&J recipe that helped earn me a first date with the woman who’d become my wife and my partner through every crisis since.
npr.org/2026/11/06/nx-s1-602…
Chris Mason retweeted
Excited to share our other recent paper in @NatureBiotech from Christina Leslie and our lab. We developed and in vivo validated DynaVelo, a deep learning tool that predicts rescue of genetic loss-of-function mutations. Brilliantly led by @karbalayghareh nature.com/articles/s41587-0…
Chris Mason retweeted
In vivo gene editing landscape.
We mapped ~60 programs across 35 companies spanning DNA, RNA and epigenetic editors delivered by LNP, AAV and other vehicles.
Some thoughts on this space:
• In the last few years, gene editing has become a commercial reality (i.e. Casgevy), but that launch has shown how hard it is to scale an ex vivo approach: cell collection logistics, myeloablative conditioning, lag time to revenue recognition and more
• Just as we're seeing in CAR-T (>$10B+ in acquisitions across Capstan, Orbital, Kelonia, Interius and EsoBiotec), there is hype around in vivo to remove a lot of those bottlenecks. Cells are edited inside the patient with a single off-the-shelf product, so there's far less manufacturing complexity
• The field is early, with just two late-stage programs: Intellia's nex-z and Ionvo-z, which share the same LNP and Cas9 mRNA. The latter in particular will set the regulatory, payor and physician precedent for the field with a March 2027 PDUFA
• The sell side is already modeling a launch ramp ~20% faster than ex vivo over the first 5 years, but a lot of this rests on physician comfort given the edit is permanent and chronic drugs already work
• Since LNPs mostly reach the liver, there's commercial overlap between late-stage RNA drugs and these editing programs (HAE, ATTR-CM, lipids). For physicians, that creates an either / or scenario between a permanent edit and a proven chronic therapy, and many may just wait and see.
• There are plenty of catalysts to watch through the end of 2026 and early 2027, including the Lonvo-z PDUFA, EDIT-401 human PoC and PM647 first data, among others
And this is just a preview - tomorrow we’re dropping the full gene therapy landscape, covering every program across editing, AAV and non-viral delivery, plus deals, China and upcoming catalysts. Leave a note below and we'll send it to you when it drops.
Chris Mason retweeted
What if a warfighter could take a drug before entering a radiation zone, and walk out with their DNA intact?
Today, they can't. Radiation remains one of the few battlefield threats with no real biological countermeasure.
@alantomusiak is building one.
In 2027 he joins our Biosecurity and Biodefense segment at @SynBioBeta as founder and CEO of Permanence Bio.
The defense community wants this badly. The demand signal spans @BARDA, @DARPA, the @ENERGY Department, the @DeptofWar, and @NASA.
Radiation exposure is on the table for:
- Troops operating after a nuclear detonation or in contaminated terrain
- Responders at a failed nuclear power plant
- Fighter pilots at altitude
- Astronauts on long-duration missions
The gap is stark. Gastrointestinal acute radiation syndrome, where radiation wipes out the gut lining, has no approved therapy. None.
Radiation is Permanence's fastest-moving program, and it already has strong animal data. Alan's team is mining old U.S. government data sets to build new radiation countermeasures for warfighters and civilians. The compounds are small molecules that shield DNA and protect the immune system and gut lining from acute exposure.
The same platform opens a second front: protecting kidneys, salivary glands, and bone marrow in cancer patients getting radioligand therapy. The long game is stopping cancer before it starts.
Alan's route in: @Stanford undergrad. Screening work at @ArsenalBio. Investing at @age1vc. A PhD at the @BuckInstitute in @EricVerdin's lab, where he built IntrinClock, an epigenetic clock published in Communications Biology in 2024. Today Permanence operates out of @MBiolabs in San Francisco. Every step pointed at the same target: genome damage.
Biodefense talk usually centers on pathogens and AI. Radiation belongs in that conversation, and Alan is bringing it.
Come find him in San Jose, May 3-6th, alongside a growing roster of government and defense speakers in our newly minted Biosecurity and Biodefense segment.
Chris Mason retweeted
2026 OSDR AWG Workshop, Dec 2 in DC, before @ASGSRSpace. Open space data for fundamental and applied biomedicine, crew health, life support ->🌘 lunar missions
Register: forms.gle/jks2y618fGbYauAQ7
Agenda: awg.osdr.space/t/register-no…
About AWGs: awg.osdr.space/about
Chris Mason retweeted
It seems the FDA has finally decided to cross the Rubicon and published a new and revolutionary regulatory framework which aims to expedite the regulatory approval process of new Gene Editing-based treatments - such as $BEAM Base Editing and $PRME Prime Editing.
These new proposed guidelines are the pinnacle of a regulatory process which began with a Cell and Gene Therapy Roundtable - held last year by FDA former commissioner @MartyMakary and the former director of the FDA’s Center for Biologics Evaluation and Research (CBER) @VPrasadMDMPH, in which researchers, industry leaders and scientists set together with FDA officials to bring new ideas to the table.
During this fascinating meeting Prof. @davidrliu from @Harvard & the @broadinstitute and most importantly the inventor of Base Editing and Prime Editing has made a closing statement which really caught my attention:
“It’s not only about treating 1,000 rare disease patients but about building a modular system that turns rare disease treatment into a national engine for therapeutic innovation and which will secure America’s leadership in Genetic medicine for the foreseeable future.”
It seems that finally Prof Liu’s call was answered!
🚨The FDA’s new draft guidance on individualized genome editing products makes base and prime editing much more practical. Good news for many patients that are still waiting.
▶️ Beam had planned full dose exploration with BEAM-304A for the common R408W mutation in PKU, then adding 304B and 304C to the same master-protocol trial starting at the optimal dose from 304A. Under the guidance, it is now possible that Beam could get approval covering 304B and 304C (and later mutations) with little or no clinical data on those variants, as long as the data from 304A are judged sufficient to support the Individualized Feature Space and the variants meet in vitro criteria.
▶️ Prime Medicine is already dosing patients in its Phase 1/2 trial for PM577a targeting H1069Q in Wilson disease, the most common mutation in US and EU (roughly 30-50%). The same framework could let clinical data on H1069Q support an IFS that covers additional ATP7B mutations, so Prime may not need separate trials for R778L and other variants in US.
I expect Beam and Prime can reach 60%+ patients in PKU and WD quickly with a few guide RNAs/pegRNAs once 304A and H1069Q are approved.
🔥 Both companies are well positioned because they hold the foundational IP in base editing and prime editing and already have modular LNP platforms that fit the IFS model.
$BEAM $PRME
Chris Mason retweeted
Lots of debate this week on whether journals should ban AI in peer review.
We actually tested this in our new preprint, and the results were pretty clear to me.
For context, I've reviewed for most of the big journals and evaluated 1,000 human reviews as an editor. I love to read and evaluate science.
TLDR: From now on I won't do any peer review without AI. For clinical trials, I'd even call human-only review dangerous 🧵
































